Table 6. Single arm meta-analysis for tr-SAE rate.

Treatment	tr-SAE	95% CI (lower)	95% CI (upper)
Chemo	0.47	0.45	0.48
Carem + Chemo	0.66	0.60	0.73
Nivo	0.19	0.16	0.22
Nivo + Ipi	0.33	0.29	0.37
Nivo + Chemo	0.56	0.48	0.63
Atez	0.13	0.09	0.17
Atez + Chemo	0.68	0.65	0.71
Pembro	0.20	0.18	0.23
Pembro + Chemo	0.66	0.63	0.69

Chemo, chemotherapy; Carem + Chemo, caremlizumab plus chemotherapy; Nivo, nivolumab; Nivo + Ipi, nivolumab plus ipilimumab; Nivo + Chemo, nivolumab plus chemotherapy; Atez, atezolizumab; Atez + Chemo, atezolizumab plus chemotherapy; Pembro, pembrolizumab; Pembro + Chemo, pembrolizumab plus chemotherapy; tr-SAE, treatment related adverse event (grade 3 and higher).